Karen A. Autio

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

31h-index4.2kcitations291works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(158), Cancer Immunotherapy and Biomarkers(97), Immunotherapy and Immune Responses(71), Radiopharmaceutical Chemistry and Applications(59), CAR-T cell therapy research(59)

Publications290 total

Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial
Clinical Cancer Research·2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
Journal of Clinical Oncology·2025· 3 cited
2385MO Translational analyses of T cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)
Annals of Oncology·2025· 1 cited
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
Investigational New Drugs·2025· 1 citedOpen Access
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Journal of Clinical Oncology·2025· 14 citedOpen Access
Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025· 3 cited
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.
Journal of Clinical Oncology·2025· 3 cited
Imaging with [ <sup>89</sup> Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with neuroendocrine tumors of the prostate: A phase 1/2, first-in-human trial.
Journal of Clinical Oncology·2025
Table S6 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S7 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S3 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S4 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S5 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S2 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S8 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Table S9 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Figure S2 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Data from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
Figure S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Michael J. Morris(19), Howard I. Scher(19), Dana E. Rathkopf(14), Daniel C. Danila(13), Susan F. Slovin(12), Wassim Abida(8), Aung Naing(7), Kyriakos P. Papadopoulos(7), Jeffrey R. Infante(6), Martin Oft(6), David B. Solit(5), Anuradha Gopalan(5), Shubham Pant(5), Johanna C. Bendell(5), Todd M. Bauer(5), Ethan Basch(5), Vincent P. Laudone(4), Victor E. Reuter(4), Michael F. Berger(4), Philip W. Kantoff(4)